scholarly journals Comprehensive Management of Daily Living Activities, behavioral and Psychological Symptoms, and Cognitive Function in Patients with Alzheimer's Disease: A Chinese Consensus on the Comprehensive Management of Alzheimer's Disease

2021 ◽  
Author(s):  
Jianjun Jia ◽  
Jun Xu ◽  
Jun Liu ◽  
Yongjun Wang ◽  
Yanjiang Wang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Function ◽  
Daily Living ◽  
Psychological Symptoms ◽  
Daily Living Activities ◽  
Comprehensive Management ◽  
Behavioral And Psychological Symptoms

Are Behavioral and Psychological Symptoms of Dementia Associated With Mortality in Alzheimer's Disease?

2000 ◽  
Vol 12 (S1) ◽  
pp. 63-66 ◽  
Author(s):  
David W. Gilley
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Daily Living ◽  
Progressive Disease ◽  
Psychological Symptoms ◽  
Substantial Reduction ◽  
Disease Characteristics ◽  
History Of ◽  
The Relationship ◽  
Behavioral And Psychological Symptoms

Alzheimer's disease (AD) is associated with a substantial reduction in life expectancy, and mortality has long been evaluated as part of the natural history of this progressive disease. Survival time also plays an important role in projecting the future public health costs of AD. There is now considerable evidence linking mortality in AD with the severity of cognitive impairment and the level of disability in common activities of daily living (Bowen et al., 1996; Jagger et al., 1995; Moritz et al., 1997); established predictors of mortality in AD are listed in Table 1. However, the relationship between mortality and other disease characteristics has received less attention.

Discussion 1

2000 ◽  
Vol 12 (S1) ◽  
pp. 73-75
Keyword(s):  
Risk Factors ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Activities Of Daily Living ◽  
Preliminary Data ◽  
Daily Living ◽  
Psychological Symptoms ◽  
The Third ◽  
Behavioral And Psychological Symptoms

Dr. Grossberg began the discussion by sharing preliminary data from a study designed to determine risk factors for institutionalization in patients with autopsy-confirmed Alzheimer's disease (AD). Initial findings from this study, which enrolled 100 patients, indicate that the principal predictor of institutionalization is behavioral and psychological symptoms of dementia (BPSD), principally agitation, aggressiveness, and problem wandering. Difficulty with activities of daily living, especially related to continence and hygiene issues, was the second most common predictor of institutionalization. The third most common predictor was lack of a caregiver, either because of death or because of other reasons.

scholarly journals Yokukansankachimpihange Is Useful to Treat Behavioral/Psychological Symptoms of Dementia

2021 ◽  
Vol 7 ◽  
Author(s):  
Eiichi Katsumoto ◽  
Toru Ishida ◽  
Kenji Kinoshita ◽  
Miho Shimizu ◽  
Toshihito Tsutsumi ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Daily Living ◽  
Rating Scale ◽  
Psychological Symptoms ◽  
Gastrointestinal Symptoms ◽  
Multicenter Studies ◽  
Dementia Patients ◽  
Loss Of Appetite ◽  
Behavioral And Psychological Symptoms

Yokukansankachimpihange is a Japanese herbal medicine reported to benefit anxiety and sleep disorders, and it has recently been introduced to treat behavioral and psychological symptoms of dementia. There are no multicenter studies of its effectiveness regarding dementia in Japan, and this study's main objective was to clarify the effects of Yokukansankachimpihange on behavioral and psychological symptoms of dementia in a sample of patients from multiple healthcare centers. Nine facilities affiliated with Osaka Association of Psychiatric Clinics participated in November 2013 through April 2015 and provided 32 Alzheimer's disease patients to whom Yokukansankachimpihange was orally administered for 8 weeks. During the study, the patients continued their regular medication regimens. Behavioral and psychological symptoms of dementia (Behavioral Pathology in Alzheimer's Disease Rating Scale [Behave-AD]), core symptoms [Mini-Mental State Examination (MMSE)], activities of daily living [Nishimura Activity of Daily Living Scale (N-ADL)], and gastrointestinal symptoms (nausea/vomiting, loss of appetite, gastric discomfort, constipation, and diarrhea) were measured at baseline, after 4 weeks of treatment and after 8 weeks of treatment. Yokukansankachimpihange was orally administered at a dosage of 7.5 g twice daily before or between meals for 8 weeks. The Behave-AD mean score significantly improved after 8 weeks of treatment. There were no significant changes in MMSE, N-ADL, or gastrointestinal symptoms; however, decreased gastrointestinal scores were observed after 8 weeks. There were no side effects related to Yokukansankachinpihange. Pharmaceutical treatments are important for treating behavioral and psychological symptoms of dementia, and this study confirmed Yokukansankachimpihange's efficacy for treating Alzheimer's disease. Because the aggressiveness and sleep disorder components of the Behave-AD construct were the symptoms most improved and those symptoms are known to significantly burden dementia patients' caregivers, Yokukansankachimpihange's efficacy might indirectly relieve these caregivers' burden of care.

scholarly journals Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Zahra Ayati ◽  
Guoyan Yang ◽  
Mohammad Hossein Ayati ◽  
Seyed Ahmad Emami ◽  
Dennis Chang
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Cognitive Function ◽  
Daily Living ◽  
Randomised Clinical Trials ◽  
Disease Assessment ◽  
Significant Difference

Abstract Background Saffron (stigma of Crocus sativus L.) from Iridaceae family is a well-known traditional herbal medicine that has been used for hundreds of years to treat several diseases such as depressive mood, cancer and cardiovascular disorders. Recently, anti-dementia property of saffron has been indicated. However, the effects of saffron for the management of dementia remain controversial. The aim of the present study is to explore the effectiveness and safety of saffron in treating mild cognitive impairment and dementia. Methods An electronic database search of some major English and Chinese databases was conducted until 31st May 2019 to identify relevant randomised clinical trials (RCT). The primary outcome was cognitive function and the secondary outcomes included daily living function, global clinical assessment, quality of life (QoL), psychiatric assessment and safety. Rev-Man 5.3 software was applied to perform the meta-analyses. Results A total of four RCTs were included in this review. The analysis revealed that saffron significantly improves cognitive function measured by the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale-Sums of Boxes (CDR-SB), compared to placebo groups. In addition, there was no significant difference between saffron and conventional medicine, as measured by cognitive scales such as ADAS-cog and CDR-SB. Saffron improved daily living function, but the changes were not statistically significant. No serious adverse events were reported in the included studies. Conclusions Saffron may have the potential to improve cognitive function and activities of daily living in patients with Alzheimer’s disease and mild cognitive impairment (MCI). However, due to limited high-quality studies there is insufficient evidence to make any recommendations for clinical use. Further clinical trials on larger sample sizes are warranted to shed more light on its efficacy and safety.

Sign in / Sign up

Export Citation Format

Share Document